• Proposals to enhance intellectual property protections to meet unmet medical needs, notably research and development of life-saving therapies; proposals to modify the Food Drug and Cosmetic Act which simplify pathways to approve patent claims.
• Proposals to maintain and strengthen patient access to needed prescription medicine and medical devices under the Medicare and Medicaid programs; advocacy for access to personalized treatment options for low income populations; supporting regulations to empower health care decisions between health care providers and patients; issues related to Administration actions which would allow patients to save out-of-pocket expenses on their prescription drugs.
• Supporting proposals to strengthen cGMP; encouraging full implementation and enforcement of the Drug Quality and Safety Act.
• Advocacy of Allergan's Social Contract with Patients to encourage greater access to innovative medicines; support for strategic, market-based international trade policies to improve patient access and intellectual property protections of life-saving therapies.
• Proposals encouraging research and development and manufacturing of potentially life-saving treatments and ensuring patient access to improve quality of life; supporting protections for patients from illegal and inappropriate exposure to counterfeit and diverted medicines; promoting new therapeutic approaches to gene therapy and tissue replacement toward unmet medical needs; education regarding emerging health care concerns surrounding rare and undiagnosed diseases; support for providing incentives to encourage development of novel anti-infective treatments to counter microbial resistant diseases; support for protecting research and development for novel diagnostics, treatments and vaccines.
• Issues relating to tax moratoriums for medical devices.
• Support for proposals to provide economic relief to small businesses and income security for affected populations in light of the coronavirus pandemic.

Duration: January 1, 2008 to May 8, 2020

General Issues: Copyright/Patent/Trademark, Medicare/Medicaid, Pharmacy, Trade (Domestic & Foreign), Health Issues, Taxation/Internal Revenue Code, Disaster Planning/Emergencies, Budget/Appropriations, Medical/Disease Research/Clinical Labs, Alcohol & Drug Abuse, Consumer Issues/Safety/Protection, Labor Issues/Antitrust/Workplace, Manufacturing, Telecommunications, Accounting, Foreign Relations

Spending: about $29,051,980 (But it's complicated. Here's why.)

It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.

Agencies lobbied since 2008: U.S. Senate, House of Representatives, Office of Management & Budget (OMB), Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), White House Office, Patent & Trademark Office (PTO), Centers For Medicare and Medicaid Services (CMS), Federal Communications Commission (FCC), U.S. Senate,, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Commerce - Dept of (DOC), Centers For Disease Control & Prevention (CDC), Medicare Payment Advisory Commission (MedPAC), Natl Institutes of Health (NIH), Veterans Affairs - Dept of (VA)

Affiliated organizations: Allergan, Inc.

Related Foreign Entities: Allergan plc (Coolock, Dublin D17 E400, IRL); contribution to lobbying: $0; ownership 100%